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  3 
Introduction 4 
Atrial fibrillation (AF) is the most common cardiac arrhythmia in clinical practice with an 5 
estimate of 1.36 million people in England living with the condition. 1 It is a major predisposing 6 
factor for stroke, increasing the risk of individuals by fivefold and contributing to 7 
approximately 20% of all ischaemic strokes. 2-4 Oral anticoagulants (OACs) have been shown 8 
to be the most effective agents for the prevention of AF-related strokes and there is extensive 9 
evidence demonstrating their underuse in practice. 5-7 Vitamin K antagonists (VKAs), 10 
predominantly warfarin, have been the main OAC used in England for prevention of AF-related 11 
strokes.7 The availability of Non-vitamin K antagonist Oral Anticoagulants (NOACs) have 12 
shown to be non-inferior to warfarin and the latest National Institute of Health and Care 13 
Excellence (NICE) guidelines for AF recommend the choice of using a VKA or a NOAC based 14 
on patients’ clinical features and preferences with a personalised package of care. 8 This 15 
intention is to encourage patients’ involvement in shared decision making as well as 16 
recognising the opportunity to minimise the reported wastage of medicines due to non-17 
adherence. 9   18 
Patients starting on VKA in England traditionally attend a dedicated anticoagulation 19 
management service for monitoring their treatment and are more closely supported by a 20 
healthcare professional upon initiation. 8,10 Option of VKA patient self-monitoring is also 21 
available and taken up by a small number of patients. 11,12  Those that are started on a NOAC 22 
do not require regular blood monitoring and guidelines recommend a first follow up 23 
appointment four weeks following treatment initiation. 13 Although these features can raise a 24 
potential concern on adherence, it is unclear whether VKAs or NOACs are a better option for 25 
  
improved adherence, since most recent studies focus on comparison of adherence patterns 26 
within NOACs. 14,15 27 
 28 
Challenges of patient adherence in the context of oral anticoagulants used for stroke prevention 29 
in AF are similar to those that arise from other long term conditions (LTC), with evidence 30 
illustrating a third to half of patients are likely to stop taking their medication, resulting in a 31 
negative impact on their quality of life, mortality and the NHS economy16-18.  Studies have also 32 
demonstrated patients are more likely to become non-adherent in the first month of being 33 
initiated a new medicine for LTCs19.  Patients newly initiated on medicines frequently 34 
encountered unmet needs for information and required additional support. Hence, an 35 
intervention, based on  a perceptions and practicalities approach 20,21, recognising adherence is 36 
influenced by beliefs and/ or symptoms that are unique to each patient was proposed, where 37 
pharmacists adopt a patient centred approach by listening to the patient, providing information 38 
and reassurance in response to expressed needs during telephone consultations.22 This 39 
intervention was shown to improve adherence and led to the development of a nationally 40 
commissioned service called New Medicine Service (NMS).  This service was implemented 41 
into practice in 2011 as part of the Advanced Services under the National Health Service (NHS) 42 
community pharmacy contractual framework, whereby community pharmacist can opt to 43 
provide the service from their pharmacy.23    44 
In 2014 an evaluation of the NMS was undertaken and showed to improve adherence by 10% 45 
to people who were started on new medication for asthma/COPD, type 2 diabetes, and 46 
hypertension or antiplatelet/anticoagulant treatment.  The NMS comprises three consultations 47 
arranged between the pharmacist and patient over a month following initiation of any new 48 
medicine in the above mentioned indications.  Each visit allows the pharmacist to determine 49 
and address patients’ lack of understanding or knowledge needs, assess any health system or 50 
  
personal barriers that may contribute to non-adherence and most importantly, facilitate 51 
appropriate interventions with individual patients’ that are tailored to support their needs24.  To 52 
undertake this role, community pharmacists acquire a number of skills and knowledge that can 53 
address the clinical and behavioural components required for supporting adherence. At present 54 
pharmacists have access to a range of learning materials developed to support the introduction 55 
of the NMS and are required to sign a declaration of competency. However, an assessment of 56 
pharmacists’ needs in providing a NMS consultation on oral anticoagulants has not been 57 
formally undertaken. 58 
 59 
Aim of the study 60 
To assess community pharmacists’ current practice, perceived skills and knowledge in 61 
supporting patients’ medication adherence as part of NMS on OAC for stroke prevention in 62 
patients with AF. Also, we intended to evaluate pharmacists’ perceived needs for additional 63 
support or education to increase the implementation of the service.  64 
 65 
Ethical approval 66 
Ethical approval was not sought because this survey was an assessment involving no changes 67 
to the current services being delivered. The questionnaire was anonymous and pharmacists 68 
were free to decline participation. As such, the principles of ethical research, such as 69 
confidentiality and anonymity, were followed. 70 
 71 
Method 72 
A cross-sectional survey was developed a) to benchmark community pharmacists’ existing 73 
practice and experience of providing a NMS on OAC for stroke prevention in patients with 74 
AF; b) to determine their knowledge and confidence in discussing OAC management with 75 
  
emphasis on supporting adherence and c) to identify training needs and pharmacists’ preference 76 
of resources for a NMS consultation.  Data were collected using an anonymous online survey 77 
that was distributed to pharmacists working within community pharmacies in London by e-78 
mail with a link through their Local Pharmaceutical Committees (LPCs).  The survey was also 79 
advertised by the Royal Pharmaceutical Society (RPS) through their local practice forum to 80 
encourage participation. 81 
 82 
A literature search identified a lack in published surveys assessing community pharmacist 83 
knowledge, skills and NMS provision on OAC for stroke prevention. Hence, questions were 84 
developed internally by author consensus and pre-testing to a sample of twenty community 85 
pharmacists and five hospital pharmacists. Feedback was used to ensure the questions were 86 
meaningful and to examine their clarity and acceptability.  Pilot results were not included in 87 
the final analysis, but used to modify and adapt the questions and format (Appendix A). Data 88 
obtained from the application of the final version was used to validate the survey (as detailed 89 
in statistical analysis), ensuring credible results. 90 
 91 
Survey 92 
The survey was designed using Survey Monkey and comprised a summary description of the 93 
study and questions designed to collate demographics and professional characteristics of 94 
pharmacists, including gender, years of experience and educational background.  The current 95 
practice of community pharmacist was determined by quantifying the NMS consultation(s) 96 
undertaken by respondents in a three month period for all commissioned LTC and more 97 
specifically oral anticoagulants. The survey was then organised in several sections, where 98 
statements were provided for participants to rate: 99 
  
a) Pharmacists’ knowledge and confidence based on their perception, subdivided into 100 
when advising patients on NOACs and on VKA(5-point Likert scale ranging from 101 
strongly agree to strongly disagree).  102 
b) Perceived helpfulness of information sources available (4-point Likert scale ranging 103 
from not helpful to very helpful) 104 
c) Attributed importance to a list of counselling information to be discussed with patients 105 
newly prescribed an OAC (4-point Likert scale ranging from critical to not important). 106 
d) Resources used during a NMS consultation for oral anticoagulants (list provided and 107 
answered as yes/no), followed by an open-ended question for those with a ‘yes’ 108 
response to enter the resource description.   109 
e) Pharmacists’ preference of support material required when discussing oral 110 
anticoagulant with patients (4-point Likert scale ranging from critical to not important), 111 
with an option of documenting additional resources and/ or tools that were not 112 
highlighted. 113 
f) Pharmacists’ views on the importance of soft skills for improving their NMS service 114 
provision for OAC (4-point Likert, ranging from very helpful to not helpful).  115 
All questions were designed with a skip pattern and respondents had the opportunity to free 116 
type additional information for each question. 117 
 118 
The first e-mail invitation was sent on the 4th December 2014 and the survey remained open 119 
until 31st January 2015. Reminder e-mails were sent on three different occasions to community 120 
pharmacists through LPCs and large multiple community pharmacies’ regional managers were 121 
also contacted directly to confirm receipt of online survey and encourage its dissemination to 122 
their London pharmacy stores. 123 
 124 
  
Sample size estimation 125 
The number of pharmacists working in community pharmacies within London was 3807, 126 
representing 28% of the workforce in community pharmacy22. Assuming that 10% of these 127 
could be delivering the NMS for OAC25, using a confidence interval of 95% and accepting a 128 
3.5% error we expected to receive 277 answers.   129 
 130 
Data analysis 131 
The data were analysed in SPSS version 23. Validation of the survey comprised confirmatory 132 
factor analysis and reliability analysis (Cronbach’s alpha). Data analysis comprised descriptive 133 
univariate statistics and bivariate analysis (Wilcoxon test). A confidence level of 95% was 134 
considered. 135 
 136 
Results 137 
A total of 269 responses were received over a two month period, of which 12 were excluded 138 
as they only contained demographic data. The majority were male (62%; n=159), with a wide 139 
range of experience in practice. Most responders were permanent members of staff. 140 
Approximately a third had undertaken further academic qualifications following their 141 
registration (table 1). 142 
Please insert table 1 here 143 
 144 
The survey’s validation indicated it comprised 5 domains, all of them with high validity, 145 
ranging from 0.676 to 0.892. Detailed information of the survey’s validity is presented in table 146 
2. 147 
Please insert table 2 here 148 
 149 
  
In a three month period, 87% of pharmacists completed one or more NMS consultations, 68% 150 
completed one or more NMS for OAC, and 35% completed one or more NMS for NOACs. 151 
Data indicates that 25% of pharmacists had completed six or more NMS consultations for all 152 
OAC, of which 11% were for NOACs (figure 1).Those with extra academic qualifications 153 
undertook more NMS for OAC (p=0.012), whilst proprietor pharmacists undertook less 154 
(p=0.035).   155 
Please insert figure 1 here 156 
 157 
Pharmacists were more confident in their knowledge, skills and access to resources for VKA 158 
than for NOAC (p<0.005). Pharmacists with extra qualifications expressed higher confidence 159 
on all the dimensions illustrated in figure 2, except for using a counselling check list, which 160 
they use as little as all pharmacists (p<0.05). The results also highlight pharmacists’ 161 
unfamiliarity with NOAC alert cards, as a significantly lower proportion checked for them in 162 
comparison with VKA alert cards (p<0.001), albeit there is also room for improvement in the 163 
latter.  Approximately 40% of the pharmacists felt uncertain or lacked the confidence in their 164 
knowledge on NOAC, comparable to 23% for VKA (figure 2).   165 
 166 
Please insert figure 2 here 167 
 168 
All counselling items were deemed important, although with varying importance (figure 3). 169 
The key priorities for pharmacist during their consultation with patient newly initiated on oral 170 
anticoagulant was firstly to discuss what actions to take when bleeding occurs, followed by 171 
supporting adherence.  In this order, the basic mode of action was perceived as the least 172 
important dimension when discussing newly initiated OAC with AF patients for stroke 173 
prevention. 174 
  
The importance of a patient’s alert card was perceived as critical to very important by 78% of 175 
pharmacists, more often by those that stated to routinely check for an alert card. Both the 176 
correlation coefficients for VKA and NOACs were statistically significant, although weak 177 
(r=0.304; p<0.001 for VKA and r=0.187; p=0.005). 178 
 179 
Please insert figure 3 here 180 
 181 
Around half the pharmacists confirmed they utilised one source of information during a NMS 182 
consultation on OAC (51%). The most frequently mentioned was the British National 183 
Formulary (BNF), the sole source utilised by a quarter of pharmacists.  Online resources were 184 
accessed by 34%, of which a third did not specify the websites used.  The most popular medical 185 
online websites named included patient websites, NHS choice, NICE clinical knowledge 186 
summaries and electronic medicine compendium to reach Patient Information Leaflets and/or 187 
Summaries of Product Characteristics.   188 
 189 
The most valued resources to have available during a NMS consultation on OAC in AF patients 190 
for stroke prevention were check-lists, followed by patient information leaflets, with 191 
insignificant differences (figure 4). 192 
 193 
Please insert figure 4 here 194 
 195 
Soft skills were acknowledged as important to attain to address the behavioural dilemmas of 196 
adherence by over 80% of pharmacists. We have considered these as less tangible constructs, 197 
not clinical and often related to social and administrative sciences, such as communication 198 
  
skills25. Within the latter, counselling skills were deemed the most necessary for an effective 199 
NMS consultation, albeit all skills were considered important (figure 5).   200 
 201 
Please insert figure 5 here 202 
 203 
The preferred training delivery methods for additional education were online educational 204 
modules (49.1% considered as very helpful), followed by clinical case studies (43.3%) and 205 
practical workshops (43.2%). The least favoured delivery methods within the list were 206 
independent study and clinical supervision, with only 24.1% and 16.7% respectively of 207 
pharmacist viewing these as very helpful.  Seminars or lectures and facilitated group 208 
discussions were seen as very helpful by 30.5% and 30.0%, respectively. 209 
 210 
Discussion 211 
Over eighty five percent of community pharmacists in London are undertaking NMS 212 
consultations, of which OAC make up a small proportion.  The DoH commissioned report for 213 
evaluating the NMS has shown antiplatelet and anticoagulants contributed to 8.5% of all NMS 214 
consultations, in line with our findings26.  NHS England latest national pharmaceutical list 215 
2013-2014 reported a quarter of community pharmacies in London do not provide NMS27.  216 
This value is above our results, finding only 13% of pharmacists did not provide this nationally 217 
commissioned service.  This suggests inconsistencies in access to the NMS services by patients 218 
in London and potentially inequalities in the care and support of adherence for their LTC 219 
medication, undermining the core principles of NHS. All AF patients initiated on oral 220 
anticoagulant for stroke prevention within London should be provided with an equal 221 
opportunity to access the NMS support systems rather than occur by chance28.    222 
 223 
  
Proprietor pharmacists were undertaking fewer NMS consultations, as indicated by the DoH 224 
report27. This finding requires further exploration to determine if independent pharmacies 225 
require support in adopting the NMS as part of routine practice, especially as the number of 226 
independent contractors in London was estimated to be 61% of total community pharmacies in 227 
2013-1427.   228 
 229 
Only for NOACs there was no positive relationship between higher education levels and the 230 
number of NMS consultations undertaken, which may largely be explained by the minimal 231 
exposure community pharmacists have to the patients initially prescribed a NOAC in London.  232 
Most current local arrangements across London for initiation of NOAC are largely dependent 233 
on shared care guidelines that require secondary care to continue supplying the first two to 234 
three months of NOAC and for most patients the NMS is not embedded as part of their care 235 
pathway.  Furthermore the uptake of NOAC prescribing in London during our survey data 236 
collection period was averaged at 6% of the total number of OAC prescriptions, resulting in 237 
less opportunity for community pharmacist to undertake a NMS consultation. Further work is 238 
required to embed the NMS on oral anticoagulant for stroke prevention in the care pathway of 239 
patients with AF as routine practice. 240 
 241 
The level of knowledge and confidence of the pharmacist responding to this survey 242 
demonstrates a wide variation, with approximately twice as many feeling uncertain or lack the 243 
confidence in their knowledge on NOAC, in comparison with VKA.  The unfamiliarity and 244 
minimal exposure to NOAC is reflected in their knowledge and confidence.  Conversely, VKA 245 
have been available for many years with national standardised recommendations and resources 246 
for patients and healthcare professionals including community pharmacists15.  These include 247 
emphasis on pharmacists’ role with the importance of ensuring patients on an OAC receive 248 
  
appropriate verbal and written information at the start and throughout their treatment including 249 
a patient safety alert card.  The availability of NOAC alert cards is currently dependent on the 250 
individual manufacturers, possibly contributing to the low proportion reporting to check for a 251 
NOAC alert card and highlights the need to make pharmacists aware and adopt a single oral 252 
anticoagulant alert card. 253 
 254 
Responding pharmacists’ primary focus during a consultation with a patient was safety 255 
followed by adherence to OAC.  This reflects the responding pharmacists’ own perceptions of 256 
their responsibilities that lay in the traditional risk averse roles and is leading to the importance 257 
of patients being able to recognise and manage bleeding as a priority to supporting adherence 258 
during their consultation. Awareness of our findings is pivotal and should be incorporated into 259 
training programmes for NMS on oral anticoagulant for prevention of AF-related strokes. 260 
Facilitating a NMS consultation requires skills beyond clinical knowledge that create the 261 
correct conditions and behaviours to support patient adherence and lead to safe and effective 262 
compassionate care. Almost all pharmacist acknowledged the importance of utilising the 263 
appropriate soft skills to build trust and a professional relationship from the start of the 264 
consultation.  Counselling and coaching skills were also deemed important by the majority for 265 
creating the correct conditions and behaviours to support patients’ adherence.  266 
There was an expressed need for a concise resource to use in practice as a reference guide or 267 
access to relevant information when undertaking a NMS consultation. The predominant 268 
resource used was BNF, containing legal and professional guidelines, focusing on the clinical 269 
effectiveness and safety of medicines but lacking information related to the process or factors 270 
impacting on adherence.  The diversity of online and other resources accessed may potentially 271 
lead to variation in the quality of information used during the consultation.  The majority of 272 
pharmacist felt the availability of a check-list and patient information leaflets (PIL) during their 273 
  
NMS consultation would be of great benefit. At present there is no single online platform that 274 
is available for pharmacist to access information and resources to support their consultation on 275 
OAC in England. The American Anticoagulation forum is an example of such a platform that 276 
could be adapted to the UK pharmacists’ needs by incorporating relevant validated tools, 277 
videos, PIL and alert cards29.   278 
Online modules were rated as the most helpful education method. The remaining methods 279 
highly rated correspond to the existing options used to deliver continuous professional 280 
development to pharmacist.  Clinical supervision was one of the least favoured, probably 281 
because it is not part of routine community practice. 282 
 283 
Strengths and Limitations  284 
Although the response rate (6.8%) was low, the sample reached was in line with the estimate. 285 
Responses originated from all geographical areas of London with a variety in their 286 
demographic characterisation, making the results here presented valuable information. 287 
Nonetheless, it should be acknowledged that the sample largely represents experienced 288 
pharmacists, limiting extrapolations. 289 
 290 
Conclusion 291 
This survey suggests that community pharmacists’ current practice in London is limited in 292 
undertaking NMS consultations for OAC, particularly for NOACs for the prevention of AF-293 
related strokes. Pharmacists perceive their knowledge and skills as having some gaps, implying 294 
there is an urgent need to revisit the currently implemented training programme for community 295 
pharmacists and to develop the most appropriate resources to support consultations, leading to 296 
wider dissemination of the service. 297 
 298 
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